Picture of Syntara logo

SNT Syntara Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-13.54%
3m-1.63%
6m-54.83%
1yr-71.89%
Volume Change (%)
10d/3m+7.78%
Price vs... (%)
52w High-73.02%
50d MA-17.64%
200d MA-44.99%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-231.39%
Return on Equity-130.21%
Operating Margin-149.54%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Syntara EPS forecast chart

Profile Summary

Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.

Directors

Last Annual
June 30th, 2023
Last Interim
December 31st, 2023
Incorporated
May 29th, 1998
Public Since
November 10th, 2003
No. of Shareholders
4,625
No. of Employees
107
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
831,006,340

SNT Share Price Performance

Upcoming Events for SNT

Full Year 2024 Pharmaxis Ltd Earnings Release

Similar to SNT

Picture of Acrux logo

Acrux

au flag iconAustralian Stock Exchange - SEATS

Picture of AFT Pharmaceuticals logo

AFT Pharmaceuticals

au flag iconAustralian Stock Exchange - SEATS

Picture of Althea group logo

Althea group

au flag iconAustralian Stock Exchange - SEATS

Picture of Anatara Lifesciences logo

Anatara Lifesciences

au flag iconAustralian Stock Exchange - SEATS

Picture of Argent BioPharma logo

Argent BioPharma

au flag iconAustralian Stock Exchange - SEATS

FAQ